Acute interstitial nephritis (AIN) is a common cause of acute kidney injury that was first described in 1898. It is most commonly caused by drugs and infections, although other aetiologies are implicated. Here we review two papers published in this issue of Clinical Kidney Journal and provide an update on current advances and controversies relating to AIN. Nussbaum and Perazella describe the diagnostic tools (namely urinary and serum biomarkers) available for AIN and highlight that there is no single test that can accurately predict the diagnosis. As such, renal biopsy remains the gold standard. Wendt et al. present findings from a 20-year retrospective study of biopsy-proven AIN. They found that a high degree of inflammation was associated with a greater chance of renal recovery, in contrast to the presence of cortical scars, which were associated with a worse outcome. There was also a significant number who required renal replacement therapy. They advocate the use of a scoring system for AIN to help direct management. We also discuss new drugs associated with AIN (in particular new anticancer drugs) and unusual forms including granulomatous AIN. Finally, we discuss the opportunities for future research and how this may impact clinical practice.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.